2026-07-11T21:38:06Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/119062026-07-09T00:05:17Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes Sanz Solas, Antonio Saiz Rodríguez, Miriam Calvo Simal, Sara Rodríguez-Veiga, Rebeca Solana-Altabella, Antonio Montesinos, Pau Labrador Gómez, Jorge This meta-analysis, comprising 24 studies, evaluated the efficacy of venetoclax (VEN) in combination with hypomethylat-ing agents (HMAs), including azacitidine (AZA) and decitabine (DEC), in untreated patients with acute myeloid leukemia (AML), comparing outcomes from clinical trials and real-world practice. No significant difference in composite complete response (CRc) rates was observed between clinical trials (52%, 95% CI: 39–65%) and real-world studies (67%, 95% CI: 47–87%). However, overall survival (OS) was significantly longer in clinical trials (13.98 months, 95% CI: 11.89–16.07) compared to real-world cohorts (9.35 months, 95% CI: 8.46–10.23; p < 0.005). In real-world studies, the VEN + HMA combination was associated with a significantly higher CRc rate (67%, 95% CI: 48–85%) compared to HMA monotherapy (17%, 95% CI: 13–21%; p < 0.005), although no significant difference in OS was observed between these groups (9.35 vs. 9.38 months; p = 0.964). These findings highlight the need to optimize the implementation of VEN + HMA regimens in clinical practice, as real-world outcomes remain inferior to those reported in clinical trials. 2026-07-08T10:45:44Z 2026-07-08T10:45:44Z 2025-08 info:eu-repo/semantics/article 0939-5555 https://hdl.handle.net/10259/11906 10.1007/s00277-025-06543-3 1432-0584 eng Annals of Hematology. 2025, V. 14, n. 9, p. 4505-4514 https://doi.org/10.1007/s00277-025-06543-3 http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional Springer